Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Enovis Corporation (ENOV) SEC Filings & Earnings Calls

EquiReason read 15 Enovis Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-09-01 — Enovis announces binding offer to acquire eCential Robotics for €155M enterprise value plus up to €35M contingent. Expected to close by year-end 2026. Deal expected to dilute adjus.

Source: SEC EDGAR filings · figures as of 2026-07-03 · read by EquiReason

ENOVEnovis CorporationFollow ENOV — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
1.2B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
5 Nov, in 12 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

1 Sep 20268-K · 7.01Enovis announces binding offer to acquire eCential Robotics for €155M enterprise value plus up to €35M contingent. Expected to close by year-end 2026. Deal expected to dilute adjusted EBITDA margin by ~100bps in 2027, with improvement in 20acquisitionopen

Figures in the filing · each found in the filing text

Free Cash Flow Conversion · FY2027$100M

Guidance

~100bps adjusted EBITDA margin headwind in 2027; FCF conversion to 50% in 2027

Management provides specific margin and FCF guidance for 2027-2029; expects near-term dilution but long-term improvement.

Risks flagged

Regulatory approval risk for acquisition closing.

“Transaction subject to regulatory approvals; expected close by year-end 2026.”

Integration risk and margin dilution in 2027.

“Expected ~100bps adjusted EBITDA margin headwind in 2027.”
Read the original on SEC EDGAR ↗
6 Aug 20268-K · 2.02Net sales $583M (+3% y/y); organic revenue growth 5; adjusted EBITDA $104M; Guidance: Revenue $2.31-2.37B, adjusted EBITDA $425-435M, adjusted EPS $3.52-3.73, FCF conversion 25%+earningsopen

Figures in the filing · each found in the filing text

net sales · Q2-2026$583M+3% y/y
organic revenue growth · Q2-20265.0%
adjusted EBITDA · Q2-2026$104M
adjusted EPS · Q2-2026$0.90

Guidance

Revenue $2.31-2.37B, adjusted EBITDA $425-435M, adjusted EPS $3.52-3.73, FCF conversion 25%+

Enovis reaffirms full-year guidance despite acknowledging a more dynamic H2 macro environment; Q2 results show solid execution.

Risks flagged

Macroeconomic environment expected to be more dynamic in H2, posing potential headwinds.

“we anticipate a more dynamic macroeconomic environment in the second half” · word for word

Integration risks from Lima acquisition and tariff impacts remain.

“risks related to Enovis’ integration of Lima; changes in government trade policies, including the implementation of tariffs” · word for word
Read the original on SEC EDGAR ↗
6 Aug 202610-QEnovis reported Q2 2026 results with revenue growth, significant gross margin expansion, and narrowed net loss.earningsopen

Figures in the filing · each found in the filing text

Net sales · Q2-2026$583M+3% y/y
Net loss attributable to Enovis Corporation · Q2-2026$-1M+97% y/y
Operating cash flow · H1-2026$99M+114% y/y
Gross margin · Q2-202661.6%
Reconstructive segment revenue · Reconstructive · Q2-2026$295M+8% y/y
Prevention & Recovery segment revenue · Prevention & Recovery · Q2-2026$288M-1% y/y

Risks flagged

High leverage and debt service costs

“Total debt $1.28B; interest expense $8.0M in Q2 2026. The company has significant debt from acquisitions.”

Restructuring execution risk

“Restructuring charges of $4.9M in Q2 2026, primarily for facility closures and severance.”

Goodwill impairment risk

“Goodwill of $709.9M and intangible assets of $1.15B represent significant balance sheet exposure.”
Read the original on SEC EDGAR ↗
19 May 20268-K · 5.02, 5.07Reported the departure of a director or principal officer (CEO/CFO change); submitted matters to a vote of security holdersSEC ↗
7 May 20268-K · 2.02Net sales $589M (+5% y/y); Organic revenue growth 3; Recon net sales growth (reported) 11; Guidance: Revenue $2.31-2.37B, adjusted EBITDA $425-435M, adjusted EPS $3.52-3.73, FCF conversion 25%+earningsopen

Figures in the filing · each found in the filing text

Net sales · total · Q1-2026$589M+5% y/y
Organic revenue growth · total · Q1-20263.0%
Recon net sales growth (reported) · Recon · Q1-202611.0%
Recon organic sales growth · Recon · Q1-20266.0%
P&R organic sales growth · P&R · Q1-20261.0%
Net loss · Q1-2026$-8M
Net loss as % of sales · Q1-20261.4%
Adjusted EBITDA · Q1-2026$104M
Adjusted EBITDA margin · Q1-202617.6%
Net loss per share · Q1-2026$-0.15

Guidance

Revenue $2.31-2.37B, adjusted EBITDA $425-435M, adjusted EPS $3.52-3.73, FCF conversion 25%+

Full-year 2026 guidance reaffirmed with confidence; management cites solid execution and stable end markets.

Risks flagged

Geopolitical tensions and tariffs pose risk to supply chain and costs.

“Risks related to escalating geopolitical tensions, implementation of tariffs, supply chain disruptions.”

Inflationary pressures could impact margins.

“Macroeconomic conditions, including the impact of inflationary pressures.” · word for word

Integration of Lima acquisition remains a risk.

“Risks related to Enovis' integration of Lima.” · word for word
Read the original on SEC EDGAR ↗
7 May 202610-QNet sales $589M (+5% y/y); Net loss $-8M; Adjusted EBITDA $104M (+19% y/y)open

Figures in the filing · each found in the filing text

Net sales · total · Q1-2026$589M+5% y/y
Net loss · total · Q1-2026$-8M
Adjusted EBITDA · total · Q1-2026$104M+19% y/y
Prevention & Recovery Net sales · Prevention & Recovery · Q1-2026$272M-0% y/y
Reconstructive Net sales · Reconstructive · Q1-2026$317M+11% y/y
Prevention & Recovery Adjusted EBITDA · Prevention & Recovery · Q1-2026$31M+1% y/y
Reconstructive Adjusted EBITDA · Reconstructive · Q1-2026$72M+29% y/y
Operating cash flow · total · Q1-2026$24M
Capital expenditures · total · Q1-2026$53M+22% y/y

Risks flagged

Foreign exchange translation risk

“Foreign currency translation ($17,381) (2026) vs $104,928 (2025)”

High leverage and debt service costs

“Interest expense, net $9,169 (2026) vs $9,188 (2025); total debt $1,325,970”
Read the original on SEC EDGAR ↗
6 Apr 2026DEF 14ACEO transition completed with Damien McDonald appointed May 12, 2025; multiple other executive changes including retirement of former CEO, departure of EVP Strategy, and planned retirement of CHRO.open

Figures in the filing · each found in the filing text

Adjusted EBITDA · FY2025$402M
Adjusted EPS · FY2025$2.24
Net Sales (as adjusted) · FY2025$2.24B
Reported Sales Growth · FY20257.0%
Organic Sales Growth · FY20256.0%
AIP Company Performance Factor · FY202592.2%
2023 PRSU Payout · FY20250.0%
Relative TSR Percentile (2023 PRSU) · FY202527.0%
CFO Retention RSU Grant Value · FY2025$2M
Employee Engagement Score · FY202581.0%

Risks flagged

Executive turnover and transition risk

“Mr. Trerotola retired from his position of CEO on May 12, 2025... On November 7, 2025, Mr. Pryor and the Company agreed that he would step down from his position as an executive officer... On December 10, 2025, Ms. Lang informed the Company of her intention to retire from her position as the Company's SVP and CHRO, effective April 3, 2026” · word for word

PRSU performance risk - relative TSR underperformance

“At the end of the three-year performance period, the Company performance, which reflected a relative TSR ranking in the 27h percentile of the Index, resulted in a payout of 0% of target.” · word for word

AIP underperformance risk

“our results fell short of our goals, leading to an overall company performance factor under the AIP of 92.2% of target for our NEOs.” · word for word
Read the original on SEC EDGAR ↗
26 Feb 202610-KFiling text is entirely boilerplate regulatory and legal descriptions; no quantified operating/financial metrics, no economic mechanisms, no guidance, no material changes.SEC ↗
26 Feb 20268-K · 2.02Net sales $2.20B (+7% y/y); organic revenue growth 6; net loss from continuing operations $1.18B; Guidance: FY2026 revenue $2.31-2.37B, adj. EBITDA $425-435M, adj. EPS $3.52-3.73earningsopen

Figures in the filing · each found in the filing text

net sales · FY2025$2.20B+7% y/y
organic revenue growth · FY20256.0%
net loss from continuing operations · FY2025$1.18B
goodwill impairment charge · FY2025$1.05B
adjusted EBITDA · FY2025$403M
adjusted diluted EPS · FY2025$3.30
Q4 net sales · Q4-2025$576M+3% y/y
Q4 net loss from continuing operations · Q4-2025$519M
Q4 adjusted EBITDA · Q4-2025$112M
Q4 adjusted diluted EPS · Q4-2025$0.95

Guidance

FY2026 revenue $2.31-2.37B, adj. EBITDA $425-435M, adj. EPS $3.52-3.73

FY2026 guidance implies 4-6% organic revenue growth and adjusted EBITDA margin improvement. Management expresses confidence in durable, capital-efficient growth.

Risks flagged

Massive goodwill impairment indicates potential overpayment for acquisitions and deterioration in business outlook.

“non-cash goodwill impairment charge of $1,050 million after evaluating the Company’s stock price and market capitalization relative to the carrying value of our Recon and P&R reporting units” · word for word

Net loss from continuing operations of $1,182 million reflects significant financial distress.

“full year net loss from continuing operations of $1,182 million” · word for word
Read the original on SEC EDGAR ↗
12 Jan 20268-K · 7.01Furnished presentation materials for a healthcare conference; no material new information disclosed.SEC ↗
15 Dec 20258-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open

Risks flagged

Key HR leadership transition; low risk due to extended transition and internal successor.

“Retirement transition agreement with base salary continuation and reduced bonus eligibility.”
Read the original on SEC EDGAR ↗
10 Dec 20258-K · 1.01, 2.03Entered a material definitive agreement (acquisition, partnership, or major contract); took on a material direct financial obligation, increasing leverageSEC ↗
14 Nov 20258-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open

Risks flagged

Management restructuring may indicate strategic shift or cost-cutting.

“Position elimination and severance agreement.”
Read the original on SEC EDGAR ↗
6 Nov 202510-QEnovis reported a massive net loss of $571.1 million in Q3 2025 due to a $548.4 million goodwill impairment, despite revenue growth of 8.6%.open

Figures in the filing · each found in the filing text

Net sales · Q3-2025$549M+9% y/y
Net loss attributable to Enovis Corporation · Q3-2025$-571M
Operating cash flow · 9M-2025$129M+411% y/y
Prevention & Recovery revenue · Prevention & Recovery · Q3-2025$291M+6% y/y
Reconstructive revenue · Reconstructive · Q3-2025$258M+12% y/y

Risks flagged

Goodwill impairment risk

“A further sustained decline in our share price and market capitalization, future cash flows, end-markets, and/or geographic markets could result in additional impairment charges that could materially affect our financial statements in any given year.” · word for word

High leverage and debt service

“Total debt $1,359.5 million as of October 3, 2025, with interest expense of $27.3 million for the nine months.”

Integration of acquisitions

“The Company completed several acquisitions in 2025 and 2024, including the large Lima acquisition, which may pose integration risks.”
Read the original on SEC EDGAR ↗
6 Nov 20258-K · 2.02Net Sales $549M (+9% y/y); Organic Sales Growth 7; Adjusted EBITDA $95M; Guidance: Adjusted EBITDA $395-405M (from $392-402M), Adjusted EPS $3.10-$3.25 (from $3.05-$3.20)earningsopen

Figures in the filing · each found in the filing text

Net Sales · Q3-2025$549M+9% y/y
Organic Sales Growth · Q3-20257.0%
Adjusted EBITDA · Q3-2025$95M
Adjusted EBITDA Margin · Q3-202517.3%
Net Loss · Q3-2025$-571M
Adjusted EPS · Q3-2025$0.75
GAAP EPS · Q3-2025$-9.99
Goodwill Impairment · Q3-2025$548M
Recon Sales Growth · Reconstructive · Q3-202512.0%

Guidance

Adjusted EBITDA $395-405M (from $392-402M), Adjusted EPS $3.10-$3.25 (from $3.05-$3.20)

Raised full-year adjusted EBITDA and EPS guidance driven by solid Q3 execution and organic growth.

Risks flagged

Goodwill impairment of $548M indicates potential overpayment for acquisitions or declining market cap.

“non-cash goodwill impairment charge of $548 million after evaluating the Company’s market capitalization relative to the carrying value of our Recon and P&R reporting units” · word for word

Tariff and supply chain risks could impact margins.

“changes in government trade policies, including the implementation of tariffs; supply chain disruptions” · word for word
Read the original on SEC EDGAR ↗

Enovis Corporation — questions

What did Enovis Corporation file recently?
15 SEC filings in the last 12 months. Latest: 8-K on 2026-09-01 — Enovis announces binding offer to acquire eCential Robotics for €155M enterprise value plus up to €35M contingent. Expected to close by year-end 2026. Deal expected to dilute adjusted EBITDA margin by ~100bps in 2027, with improvement in 20

Every figure on this page comes from Enovis Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.